Navigation Links
Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
Date:5/25/2010

NEW ORLEANS, May 25 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the results of a study evaluating the safety and efficacy of Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years.  The data, presented in an oral session at a national scientific meeting of psychiatrists in New Orleans, LA, demonstrated that treatment with Vyvanse (30, 50, and 70 mg/d) significantly improved ADHD symptoms compared to placebo in adolescents with ADHD.

Vyvanse is currently indicated for the treatment of ADHD in children aged 6 to 12 years and in adults.  Recently, Shire submitted a supplemental New Drug Application (sNDA) for use of Vyvanse in the treatment
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Pittcon Organizing Committee is pleased ... Safety Tech , an e-Journal and producer of ... the second year for the co-location of Food Labs Conference ... provides that the registration fee to attend the two-day Food ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Look inside ... hard-working items for the lab, from fluid handling to ... (GIS)—ready to ship when you order. , Preferred ... Pumps , from the L/S® model for precise flow ...
(Date:1/15/2014)... California , January 15, 2014 Oxford ... today announced the appointment of Thomas C Reynolds MD, PhD ... years, development experience gained in the biotechnology industry, most recently ... am delighted to welcome Tom at this transformative time for ...
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... Sept. 25 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: ... on researching,developing, manufacturing and marketing biopharmaceutical products,primarily ... filed with the Chinese,State Food and Drug ... IU,dosage formulation of EPIAO for the treatment ...
... of Business ... Development Activities -, LA JOLLA, Calif., Sept. ... it will transition from a,discovery and development company to a development-only ... will,streamline operations through the shut down of its discovery operations,and seek ...
... Cells and Other ... Development Programs, ROCKVILLE, Md., ... immunotherapeutics to treat,autoimmune disorders, cancer and infectious diseases, today announced that,it ... led by,Nextech Venture, included additional new investors Arcus Ventures, Innovis,Investments and ...
Cached Biology Technology:3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO 23SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO 3TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 2TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 3TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 4MacroGenics Raises $25M in Series D-2 Financing 2MacroGenics Raises $25M in Series D-2 Financing 3MacroGenics Raises $25M in Series D-2 Financing 4
(Date:7/9/2014)... era of increasing concern about the prevalence of ... a promising new pathway to disabling disease: blocking ... The scientists showed how bacterial siderophore, a small ... to fan bacterial growth as well as ... this infection process. Their findings appear in a ...
(Date:7/9/2014)... first-ever global census of Adlie penguins shows that ... 53 percent larger than previously estimated. Adlie penguins ... to monitor and understand the effects of climate ... By using high-resolution satellite imagery, researchers from Stony ... a new method that permits regular monitoring of ...
(Date:7/9/2014)... accrue. To completely and systematically archive this body ... researchers in the life sciences spend a quarter ... online survey of 70 people working in biology ... Information Technology FIT in Sankt Augustin. Many of ... or structured approach to data collection in their ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3Managing the data jungle 2Managing the data jungle 3
... Traffic accidents involving wildlife are on the rise in Europe. ... be useful for increasing safety and preventing human and animal ... researchers have established at what time, on what day of ... roe deer are most likely to take place. Car ...
... that cancerous tumors grow collections of abnormal blood cells, the ... new evidence in an animal model suggests that blood vessels ... same purposeand could provide the key to a new way ... L. Makey, Edmund Chinchar, Carissa Howie, and Lucio Miele, all ...
... Animal sanctuaries can play an important role in rehabilitating goats ... scientists at Queen Mary, University of London. In ... moods in 18 goats, nine of which had endured poor ... shelter before arriving at a sanctuary. They created a spatial ...
Cached Biology News:Roe deer more likely to be run over at nightfall on a Sunday in April 2Drug reduces fat by blocking blood vessels 2Drug reduces fat by blocking blood vessels 3Rescue me: New study finds animals do recover from neglect 2
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
POU domain, class 2, transcription factor 2,...
HSPBP1 Antibody...
golgi reassembly stacking protein 2, 55kDa...
Biology Products: